PRESS RELEASE
June 6, 2023

Rebirthel Co., Ltd.
Room 311, Creation Core Kyoto Mikuruma
448-5 Kajii-cho, Kamigyo-ku, Kyoto, Japan 602-0841
Phone: (81) 75-212-3770
URL: https://rebirthel.com/en/
Rebirthel Co., Ltd.

Rebirthel signs Strategic Alliance Agreement with H.U. Group Research Institute G.K.
to develop next-generation immune cell therapy based on Rebirthel’s patented
technology to produce universal allogeneic T cells
Kyoto -Rebirthel Co., Ltd. (Rebirthel) announced that it has entered into a strategic

alliance agreement with H.U. Group Research Institute G.K. (H.U. Group) on April 1, 2023
to develop next-generation immune cell therapy based on Rebirthel's technology toproduce universal allogenic T cell*1.
In recent years, “autologous immune cell therapy*2” using patient’s own cells has beenrecognized as an effective treatment for certain types of cancers. However, there aresome issues: it can only be used for the donor patient; it is a burden on the patient's
body; it takes long to start the treatment; the cost is high; and heterogeneous quality.
In addition, infectious diseases require rapid treatment but autologous cell therapy
cannot immediately provide killer T cells*3. As a result, there is currently no existing celltherapy for infectious diseases. To address these limitations, Rebirthel provides acompletely novel “allogeneic immune cell therapy”. Specifically, this method uses
pluripotent stem cells as a source material and regenerates them into immune cells thatspecifically recognize and kill cancers or viruses.

H.U. Group Research Institute G.K. was established in July 2017 to consolidate basic
research functions under the H.U. Group for development of products and services thatwill benefit society in the medium and long term. H.U. Group focuses on i) innovative
analysis platforms, ii) basic medical innovation technologies, and iii) medical informationwww.rebirthel.com
1

utilization. They are actively promoting open innovation with external research
institutions, joint ventures, and different industries.
With a philosophy of rapid testing and development, H.U. Group aims to lead theindustry by establishing new businesses. These include cell therapy and regenerative
medicine, expanding advanced therapeutic modalities for future treatment. They aim tocreate new value in the healthcare field beyond testing and analysis.
H.U. Group and Rebirthel have begun joint research to add new-generation functions tothe universal allogeneic immune cell therapy technology that Rebirthel is developing forclinical application. Through this strategic alliance, H.U. Group and Rebirthel will
anticipate the needs of the next-generation of allogeneic immune cell therapies andaccelerate research and development to provide them to society.
We believe allogeneic immune cell therapy will become a mainstream treatment incancer immunotherapy. The history of biotechnology shows that even the mostadvanced technology can become outdated if it doesn’t meet society’s requirements forimproved function. With this partnership, we aim to develop a more highly advanced
functional allogeneic immune cell therapy and deliver it to patients who urgently requireit.
< Epexegesis >*1 Allogeneic T cell: Using pluripotent stem cells (cells derived from others, not from thepatient himself/herself) such as iPS and ES cells as material, T cells are regenerated andused for treatment.
*2 Autologous immune cell therapy: This therapy collects the patient's own cells andgives them back after transducing and expanding.
*3 Killer T cell: A type of cell that specifically recognizes variant cells (e.g., cancer cells)and viruses in the human body and controls immunity to attack and kill them.

www.rebirthel.com
2